Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes

European Journal of Clinical Pharmacology

Volumn 57, Issue 12, 2002, Pages 847-851

  He, Nu ^a   Zhang, Wen Qi ^b   Shockley, Dolores ^b   Edeki, Timi ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

CYP2C9; CYP2D6; H1 antihistamines

Indexed keywords

ANTIHISTAMINIC AGENT; BUFURALOL; CHLORPHENIRAMINE; CYCLIZINE; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DIPHENHYDRAMINE; PROMETHAZINE; TOLBUTAMIDE; TRIPELENNAMINE; CYP2C9 PROTEIN, HUMAN; CYTOCHROME P450; ENZYME INHIBITOR; ETHANOLAMINE DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST; STEROID 16ALPHA MONOOXYGENASE; STEROID MONOOXYGENASE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROXYLATION; IC 50; LIVER MICROSOME; METABOLITE; PLASMA; PRIORITY JOURNAL; DRUG ANTAGONISM; METABOLISM;

ARYL HYDROCARBON HYDROXYLASES; CHLORPHENIRAMINE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; ETHANOLAMINES; HISTAMINE H1 ANTAGONISTS; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; PROMETHAZINE; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TOLBUTAMIDE;

EID: 0036482802     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-001-0399-0     Document Type: Article

References (32)

1. 1-antihistamines
2. Medical implications of HGP's sequence of chromosome 22
3. Clinical importance of genetic polymorphism of drug oxidation
4. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes
5. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methylhydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations
6. Biochemistry and molecular biology of the human CYP2C subfamily
7. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism
8. 1-receptor antagonists
9. Idiosyncratic pharmacokinetics complicating treatment of major depression in an elderly woman
10. 1 antagonist promethazine in human liver microsomes
11. In vitro methods for assessing human hepatic drug metabolism: Their use in drug development
12. i) and type of inhibition
13. Genetic polymorphism in drug oxidation: In vitro studies of human debrisoquin 4-hydroxylase and bufuralol 1′-hydroxylase activities
14. The use of tolbutamide as a substrate probe for human hepatic cytochrome P4502C9
15. Cytochrome P450 inhibitors evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes
16. Inhibition of sparteine oxidation in liver by tricyclic antidepressants and other drugs
17. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin p-hydroxilation
18. The role of CYP2C in the in vitro bioactivation of the contracetive steroid desogestrel
19. Prediction of in vivo drug-drug interaction between tolbutamide and various sulfonamides in humans based on in vitro experiments
20. Determination of tolbutamide hydroxylation in rat liver microsome by high-performance liquid chromatography: Effect of psychoactive drugs on in vitro activity
21. Simultaneous determination of codeine and chlorpheniramine in human plasma by capillary column gas chromatography
22. Pharmacokinetics of diphenhydramine and demethylated metabolite following intravenous and oral administration
23. Rotary pursuit, a measure of human performance, and plasma concentration of promethazine
24. High-performance liquid chromatographic analysis of cyclizine and its metabolite, norcyclizine, in biological fluids using solid phase extraction
25. The pharmacokinetics of pentazocine and tripelennamine
26. Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2
27. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers-N-desisopropylation is mediated mainly by CYP1A2
28. Venlafaxine oxidation in vitro is catalysed by CYP2D6
29. Determination of Michaelis constants and inhibitor constants
30. Rates of enzymatic reaction
31. In vitro metabolic interaction studies: Experience of the Food and Drug Administration
32. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity